Postoperative oxygenation assessed by SpO2/FiO2 ratio and respiratory complications after reversal of neuromuscular block with Sugammadex or neostigmine: A retrospective cohort study.

[1]  M. Todd,et al.  2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade , 2023, Anesthesiology.

[2]  T. Fuchs-Buder,et al.  Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. , 2022, European journal of anaesthesiology.

[3]  K. Ulm,et al.  How robust are the STRONGER and STIL-STRONGER studies? , 2022, British journal of anaesthesia.

[4]  A. Turan,et al.  Tidal Volume and Positive End-expiratory Pressure and Postoperative Hypoxemia during General Anesthesia: A Single-center Multiple Crossover Factorial Cluster Trial , 2022, Anesthesiology.

[5]  M. Sjoding,et al.  Association between the choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study. , 2022, British journal of anaesthesia.

[6]  A. Troelsen,et al.  Postoperative complications: an observational study of trends in the United States from 2012 to 2018 , 2021, BMC Surgery.

[7]  A. Delaney,et al.  Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial , 2021, Anesthesiology research and practice.

[8]  B. Turlach,et al.  Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: a prospective, randomised, double-blind trial in high-risk older patients. , 2021, British journal of anaesthesia.

[9]  C. Hayhurst,et al.  Postoperative Pulmonary Complications’ Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis , 2021, Anesthesiology.

[10]  X. Combes,et al.  Assessment of the SpO2/FiO2 ratio as a tool for hypoxemia screening in the emergency department , 2021, The American Journal of Emergency Medicine.

[11]  T. Homma,et al.  Utility of SpO2/FiO2 ratio for acute hypoxemic respiratory failure with bilateral opacities in the ICU , 2021, PloS one.

[12]  Yang Wang,et al.  Continuously available ratio of SpO2/FiO2 serves as a noninvasive prognostic marker for intensive care patients with COVID-19 , 2020, Respiratory Research.

[13]  K. Leslie.  Sugammadex and Postoperative Pulmonary Complications: Is Stronger Evidence Required? , 2020, Anesthesiology.

[14]  R. Soto,et al.  Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER) , 2020, Anesthesiology.

[15]  M. Treggiari,et al.  Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. , 2020, British journal of anaesthesia.

[16]  L. Jameson,et al.  Hypoxemia Within the First 3 Postoperative Days Is Associated With Increased 1-Year Postoperative Mortality After Adjusting for Perioperative Opioids and Other Confounders , 2019, Anesthesia and analgesia.

[17]  P. Aggarwal.  Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis , 2019, Therapeutic advances in drug safety.

[18]  D. Sessler,et al.  Intra-operative high inspired oxygen fraction does not increase the risk of postoperative respiratory complications: Alternating intervention clinical trial , 2019, European journal of anaesthesiology.

[19]  A. Hoeft,et al.  Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. , 2019, The Lancet. Respiratory medicine.

[20]  E. Mascha,et al.  Incidence of complications in the post-anesthesia care unit and associated healthcare utilization in patients undergoing non-cardiac surgery requiring neuromuscular blockade 2005-2013: A single center study. , 2017, Journal of clinical anesthesia.

[21]  A. Afshari,et al.  Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. , 2017, The Cochrane database of systematic reviews.

[22]  Las Vegas investigators.  Epidemiology, practice of ventilation and outcome for patients at increased risk of postoperative pulmonary complications , 2017, European journal of anaesthesiology.

[23]  A. Lumb,et al.  Postoperative pulmonary complications , 2017, British journal of anaesthesia.

[24]  F. Zarantonello,et al.  Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. , 2016, Journal of clinical anesthesia.

[25]  Jesse M. Ehrenfeld,et al.  Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia , 2016, Anesthesiology.

[26]  C. Meistelman,et al.  Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia? , 2016, Current opinion in anaesthesiology.

[27]  C. Fernández-Pérez,et al.  A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade , 2015, Anaesthesia.

[28]  Jarrod E Dalton,et al.  Postoperative Hypoxemia Is Common and Persistent: A Prospective Blinded Observational Study , 2015, Anesthesia and analgesia.

[29]  O. Gajic,et al.  SpO2/FiO2 Ratio on Hospital Admission Is an Indicator of Early Acute Respiratory Distress Syndrome Development Among Patients at Risk , 2015, Journal of intensive care medicine.

[30]  H. Feußner,et al.  Neuromuscular blockade improves surgical conditions (NISCO) , 2015, Surgical Endoscopy.

[31]  Jong-Yeon Park.  Benefits and risks of sugammadex , 2015, Korean journal of anesthesiology.

[32]  M. R. Gätke,et al.  Neuromuscular blockade for optimising surgical conditions during abdominal and gynaecological surgery: a systematic review , 2015, Acta anaesthesiologica Scandinavica.

[33]  B. Hindman,et al.  The Implementation of Quantitative Electromyographic Neuromuscular Monitoring in an Academic Anesthesia Department , 2014, Anesthesia and analgesia.

[34]  Jesse M. Ehrenfeld,et al.  Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study , 2012, BMJ : British Medical Journal.

[35]  L. Booij.  Cyclodextrins and the emergence of sugammadex , 2009, Anaesthesia.

[36]  J. Vender,et al.  Residual Neuromuscular Blockade and Critical Respiratory Events in the Postanesthesia Care Unit , 2008, Anesthesia and analgesia.

[37]  R. Bender,et al.  Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. , 2002, Journal of clinical epidemiology.

[38]  L. Skovgaard,et al.  Residual neuromuscular block is a risk factor for postoperative pulmonary complications A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium , 1997, Acta anaesthesiologica Scandinavica.

[39]  H. Kehlet,et al.  Postoperative mental confusion--association with postoperative hypoxemia. , 1992, Surgery.

[40]  A. Hoeft,et al.  Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data. , 2019, British journal of anaesthesia.

[41]  Hude Quan,et al.  Association of postoperative complications with hospital costs and length of stay in a tertiary care center , 2006, Journal of General Internal Medicine.